20
Dr Reddys Laboratories Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
One of their notable products is BORTEZOMIB, with a corresponding US DMF Number 23996.
Remarkably, this DMF maintains an Active status since its submission on July 26, 2010, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 30, 2023, and payment made on June 27, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II